← All stories
Markets
What Did Celadon Pharmaceuticals (LSE:CEL) Prove Before It Left The Public Market?
Highlights Admission to the growth market was cancelled following a suspension over late accounts. The company had built domestic cultivation capacity supplying prescription channels. Board changes accompanied the departure from the public…
Covered by 1 outlet
All coverage · 1 article